Navigation Links
Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
Date:4/1/2008

BZL101 selectively kills cancer cells but not normal cells

EMERYVILLE, Calif., April 1 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI) today announced the publication of a peer-reviewed article in the journal Cancer Biology and Therapy that elucidates the molecular mechanisms underlying selective cytotoxic activity of BZL101, the company's drug for advanced breast cancer.

"BZL101 induces cell death in breast cancer cells but not in normal breast cells," said Emma Shtivelman, Ph.D., Director of Cancer Research at Bionovo. "This selective cell killing is based on strong induction by BZL101 of reactive oxygen species (ROS) in tumor cells. The ROS cause extensive DNA damage in tumor cells but not in normal cells, which then leads to the inhibition of glycolysis selectively in tumor cells. This action is most clearly evident from the decrease in the enzymatic activities within the glycolytic pathway and the inhibition of lactate production. The observed inhibition of glycolysis is a key factor in the energetic collapse and death that occurs selectively in breast cancer cells, 'selectively' because tumor cells rely on glycolysis for energy production."

Separately, Isaac Cohen, O.M.D., Bionovo's Chairman and CEO, stated, "The promising selectivity of BZL101 towards cancer cells is based on metabolic differences between highly glycolytic tumor cells and normal cells. Coupled with promising clinical development, BZL101 has the potential to be an important treatment for women with breast cancer, as well as potentially for other cancers. BZL101 could fill an important unmet medical need in cancer treatment."

About BZL101

BZL101 is an oral drug designed for the treatment of advanced breast cancer and panc
'/>"/>

SOURCE Bionovo Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers
3. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
4. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
5. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
6. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
7. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
8. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
9. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... VIENNA , April 23, 2010 AFFiRiS ... II clinical testing.,It may therefore be possible to confirm the ... start of this efficacy study comes only five,months after the ... in several disease areas and is currently developing a total ...
... LONDON , April 23, 2010 , , ... Managing uncertainty; A Migraine For Pharma Forecasters , , , ... has its up,s and down,s, with new markets,and products proving more complex and requiring sophisticated approaches to,forecast ... Dealing with uncertainties is no easy task. With ...
Cached Medicine Technology:AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 2AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 3AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 4MarketsandMarkets Partners With Eyeforpharma For The Pharma Forecasting Excellence Europe 2010 Summit 2MarketsandMarkets Partners With Eyeforpharma For The Pharma Forecasting Excellence Europe 2010 Summit 3
(Date:4/15/2014)... pre-diabetes in the United States have nearly doubled since 1988, ... Public Health, with obesity apparently to blame for the surge. ... has not hit all groups equally, with alarming increases in ... new research reported in the April 15, 2014 issue of ...
(Date:4/15/2014)... School of Medicine have identified a mechanism that explains why ... why the virus is able to persist in the body ... an estimated 200 million people worldwide, attacks the liver cells, ... ability to fight infection. It does this by altering cells ...
(Date:4/14/2014)... and American Associations for Dental Research (IADR/AADR) have published ... Oral, and Craniofacial Manifestations." The complete review by researchers ... Michael Collins, Brian L. Foster, Rachel I. Gafni, Janice ... J. Timothy Wright is published in the OnlineFirst portion ...
(Date:4/14/2014)... Orange, NJ. April 10, 2014. John DeLuca, PhD, and ... Biogen Idec to study how persons with multiple sclerosis ... Use of Actual Reality to Measure Everyday Life Functional ... this research. Dr. DeLuca is senior VP of Research ...
(Date:4/14/2014)... A new study identifies a molecule that is a ... molecule could be an important target for colorectal cancer treatment ... of microRNA-135b (miR-135b) in two animal models and human tumors ... was led by researchers at The Ohio State University Comprehensive ...
Breaking Medicine News(10 mins):Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Breaking bad mitochondria 2Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2Health News:Study identifies a likely key driver of colorectal cancer development and progression 2
... an 8-year-old boy,living with epilepsy, and his mother Amy ... Inc., the exclusive sponsor of Canine,Assistants seizure response dogs. ... him to play sports, take,music lessons, and learn Tae ... seizure when his parents are not around is still ...
... Mass., April 16 Xceed Molecular, a ... analysis,systems, announced that the University of Florida ... work with primary researchers,Charles Joel Rosser, MD ... of Surgery), to perform initial verification and ...
... April 16 Consumer,Watchdog today joined L.A. City ... that health insurer Blue Cross engaged in unfair,business ... patients,after they got sick., The practice -- ... hundreds,of patients who have been left uninsured, uninsurable, ...
... Pa., April 16 Law Offices of ... potential claims against Inverness,Medical Innovations, Inc. ("Inverness ... securities law violations by Inverness Medical and,certain ... Company,s secondary,public offering on or about November ...
... Participating Courtesy of TriWest -, PHOENIX, April ... protect America,s freedoms in Iraq and Afghanistan, Marines,Chris ... injuries diminish,their spirits. Both received prosthetic limbs, returned ... courtesy of TriWest Healthcare Alliance., As members ...
... Help Build Healthy Communities, VICTORVILLE, Calif., April ... the Victorville Earth Day Eco Tote giveaway.,On Tuesday, ... offices will be handing out recyclable Eco Totes ... the Reduce, Reuse, Recycle program, Heritage Victor Valley,Medical ...
Cached Medicine News:Health News:Young Boy With Epilepsy to Gain Independence With New Seizure Response Dog From Canine Assistants 2Health News:Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer 2Health News:Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer 3Health News:Consumer Watchdog Applauds L.A. City Attorney's Efforts to Reinstate Cancelled Blue Cross Patients; Urges State HMO Regulator to Do Same 2Health News:Wounded Marines Running Their Way to Recovery at Fourth Annual Pat's Run 2Health News:Wounded Marines Running Their Way to Recovery at Fourth Annual Pat's Run 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: